Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Wave Life Sciences (WVE) Cash from Investing Activities (2016 - 2025)

Historic Cash from Investing Activities for Wave Life Sciences (WVE) over the last 11 years, with Q3 2025 value amounting to -$248000.0.

  • Wave Life Sciences' Cash from Investing Activities rose 3524.8% to -$248000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$805000.0, marking a year-over-year increase of 3336.09%. This contributed to the annual value of -$938000.0 for FY2024, which is 1587.44% up from last year.
  • Wave Life Sciences' Cash from Investing Activities amounted to -$248000.0 in Q3 2025, which was up 3524.8% from -$306000.0 recorded in Q2 2025.
  • In the past 5 years, Wave Life Sciences' Cash from Investing Activities ranged from a high of $24.8 million in Q4 2022 and a low of -$50.2 million during Q1 2022
  • For the 5-year period, Wave Life Sciences' Cash from Investing Activities averaged around -$241421.1, with its median value being -$198000.0 (2023).
  • Over the last 5 years, Wave Life Sciences' Cash from Investing Activities had its largest YoY gain of 16570000.0% in 2022, and its largest YoY loss of 4638888.89% in 2022.
  • Quarter analysis of 5 years shows Wave Life Sciences' Cash from Investing Activities stood at -$15000.0 in 2021, then soared by 165700.0% to $24.8 million in 2022, then tumbled by 101.43% to -$356000.0 in 2023, then skyrocketed by 75.84% to -$86000.0 in 2024, then tumbled by 188.37% to -$248000.0 in 2025.
  • Its Cash from Investing Activities was -$248000.0 in Q3 2025, compared to -$306000.0 in Q2 2025 and -$165000.0 in Q1 2025.